A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Fluorouracil
Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-048
Sponsors Merck Sharp & Dohme Corp.

08 Nov 2024 According to Cue Biopharma media release , company has presented data of Phase 2 dose (RP2D) of 4mg/kg in combination with pembrolizumab in 1L HPV+ R/M HNSCC patients trial comparing the data of this trial of ORR at the Society for Immunotherapy of Cancers 39th Annual Meeting (SITC 2024) being held in Houston, Texas
28 Jun 2024 According to ClinicalTrials.gov record, 12 new therapeutic primary endpoints added.
01 Oct 2023 Results published in the International Immunopharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com